Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Tapan Kadia, MD
CONTACT
Lead
M.D. Anderson Cancer Center
Primary Objective: • To evaluate the safety and tolerability of Ruxolitinib in combination with Cladribine and Venetoclax in patients with R/R T-PLL. Secondary Objectives: * To evaluate the EFS in patients with T-PLL treated with Ruxolitinib in combination with Cladribine and Venetoclax. * To evaluate response (CR, including CRi, or PR) of Ruxolitinib in combination with Cladribine and Venetoclax in patients with T-PLL. * To assess the time to response, response duration, and OS in patients with T-PLL treated with Ruxolitinib in combination with Cladribine and Venetoclax. Exploratory Objective: • To explore correlation of genomic profile, baseline patient and disease characteristics, and response to BCL-2 inhibition.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
